CASI Pharmaceuticals Inc (OQ:CASI)
Business Focus: Pharmaceuticals
Apr 08, 2024 05:00 pm ET
CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTAS
BEIJING, April 8, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported that it has furnished a current report on Form 6-K to disclose material development relating to its dispute with Juventas. For details, please visit below link:
Mar 28, 2024 07:00 am ET
CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2023 BUSINESS AND FINANCIAL RESULTS
BEIJING, March 28, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported business and financial results for the year ended December 31, 2023, and provided an update on key highlights for 2023.
Feb 16, 2024 06:00 am ET
CASI PHARMACEUTICALS ANNOUNCES FIRST DOSING OF FOLOTYN® IN CHINA
BEIJING, Feb. 16, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and pharmaceutical products, proudly announced the administration of the first dose of FOLOTYN® (Pralatrexate Injection) to a patient in China. This remarks a pivotal step in CASI's commitment to addressing critical medical needs in peripheral T-cell lymphoma in China market.
Nov 14, 2023 06:00 am ET
CASI PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2023 BUSINESS AND FINANCIAL UPDATES
BEIJING, Nov. 14, 2023 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported business and financial results for the third quarter ended September 30, 2023.
Nov 08, 2023 06:00 am ET
CASI PHARMACEUTICALS ANNOUNCES MARKET APPROVAL OF CNCT19 BY CHINA NMPA
BEIJING, Nov. 8, 2023 /PRNewswire/ -- CASI Pharmaceuticals Inc. (Nasdaq: CASI), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, is thrilled to announce a major milestone in its partnership with Juventas Cell Therapy Ltd. (Juventas). The China National Medical Products Administration (NMPA) has granted market approval for Juventas' investigational cell therapy, Inaticabtagene Autoleucel (CNCT 19), for the treatment of relapsed and refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) in China.
Nov 02, 2023 09:31 am ET
Thinking about buying stock in NXU, AERWINS Technologies, Chevron, CASI Pharmaceuticals, or Aldeyra Therapeutics?
NEW YORK, Nov. 2, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NXU, AWIN, CVX, CASI, and ALDX.
Aug 01, 2023 07:00 am ET
Mundipharma International Corporation Limited, Mundipharma Medical Company, and Acrotech Biopharma Inc. Enter Agreement to Transfer License of FOLOTYN® (Pralatrexate) in China to CASI Pharmaceuticals
BEIJING, Aug. 1, 2023 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced the execution of an Assignment Agreement (the "Agreement") with Mundipharma International Corporation Limited ("MICL"), Mundipharma Medical Company ("MMCo"), and Acrotech Biopharma Inc. ("Acrotech") for the commercialization of FOLOTYN® (Pralatrexate) in the People's Republic of China ("China").
Jul 20, 2023 08:00 am ET
CASI Pharmaceuticals Acquires Global Intellectual Property Rights to Cleave Therapeutics' VCP/P97 Inhibitor CB-5339
BEIJING, July 20, 2023 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced the execution of the Assignment Agreement (the "Agreement") with Cleave Therapeutics, Inc. ("Cleave"), pursuant to which CASI obtained all rights and global intellectual property rights related to CB-5339, a novel VCP/p97 inhibitor, as well as all remaining CB-5339 drug substance and drug product. Additionally, CASI will assume responsibility of the United States ("US") CB-5
May 17, 2023 07:35 am ET
CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2023 FINANCIAL RESULTS
BEIJING, May 17, 2023 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman Islands incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported financial results for the three months ended March 31, 2023.
Apr 26, 2023 09:35 am ET
CASI Pharmaceuticals Files Annual Report on Form 20-F for Fiscal Year 2022
BEIJING, April 26, 2023 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ: CASI) ("CASI" or the "Company"), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2022, with the U.S. Securities and Exchange Commission ("SEC") on April 26, 2023. The annual report can be accessed on the Company's investor relations website at https://www.casipharmaceuticals.com/investor-relations/ as well as the SEC's website at https://www.sec
Apr 26, 2023 07:00 am ET
CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2022 FINANCIAL RESULTS
BEIJING, April 26, 2023 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported financial results for the year ended December 31, 2022, and provided an update on key highlights for 2022.
Mar 21, 2023 04:30 pm ET
CASI PHARMACEUTICALS COMPLETES REDOMICILIATION MERGER
BEIJING, March 21, 2023 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ: CASI) ("CASI" or the "Company"), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced that the redomiciliation merger to redomicile the Company as a Cayman Islands company (the "Redomiciliation Merger") has been completed.
Jan 06, 2023 06:00 am ET
CASI PHARMACEUTICALS AND CLEAVE THERAPEUTICS ANNOUNCE CLINICAL TRIAL APPLICATION APPROVAL FOR CB-5339 IN PATIENTS WITH MULTIPLE MYELOMA IN CHINA
~ NMPA approved CB-5339 CTA for Multiple Myeloma indication ~
Dec 15, 2022 06:00 am ET
CASI PHARMACEUTICALS' PARTNER JUVENTAS ANNOUNCES NEW DRUG APPLICATION FOR CNCT19 ACCEPTED BY CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION
ROCKVILLE, Md. and BEIJING, Dec. 15, 2022 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announces that China National Medical Products Administration (NMPA) has accepted the new drug application (NDA) from Juventas Cell Therapy, Ltd., (Juventas) for CNCT19 (Inaticabtagene Autoleucel), an investigational CD-19 directed CAR-T therapy, for the treatment of adult patients with relapsed/refractory B-Cell Acute Lymphoblastic Leukemia (r/r B-ALL).
Nov 14, 2022 06:00 am ET
CASI PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2022 FINANCIAL RESULTS
ROCKVILLE, Md. and BEIJIN, Nov. 14, 2022 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported financial results for the third quarter of 2022.
Sep 23, 2022 07:00 am ET
CASI PHARMACEUTICALS ANNOUNCES EXIT OF JUVENTAS INVESTMENT TO STRENGTHEN BALANCE SHEET
ROCKVILLE, Md. and BEIJING, Sept. 23, 2022 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products ("CASI"), today announced that CASI Biopharmaceuticals (Wuxi) Co., Ltd, a subsidiary of CASI Pharmaceuticals, Inc. ("CASI Wuxi"), entered into an Equity Transfer Agreement with Shenzhen Jiadao Gongcheng Equity Investment Fund, LLP ("Jiadao Gongcheng"), pursuant to which CASI Wuxi agreed to transfer its equity interest in Juventas Biotechnology (Tianjin) Co., Ltd.("Ju
Sep 07, 2022 07:00 am ET
CASI PHARMACEUTICALS AND BIOINVENT ANNOUNCE DOSING OF FIRST PATIENT IN BI-1206 PHASE 1 CLINICAL TRIAL FOR THE TREATMENT OF RELAPSED/REFRACTORY NON-HODGKIN'S LYMPHOMA IN CHINA
ROCKVILLE, Md. and LUND, Sweden, Sept. 7, 2022 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, and BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced the first-patient-in in China Phase 1 dose-escalation and expansion study of BI-1206, a first-in-class fully human monoclonal antibody
Aug 12, 2022 07:00 am ET
CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2022 FINANCIAL RESULTS
ROCKVILLE, Md. and BEIJING, Aug. 12, 2022 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported financial results for the second quarter of 2022.
Aug 05, 2022 08:38 am ET
CASI PHARMACEUTICALS TO REPORT SECOND QUARTER 2022 FINANCIAL RESULTS AND HOST CONFERENCE CALL AUGUST 12, 2022
ROCKVILLE, Md. and BEIJING, Aug. 5, 2022 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced the Company will host a conference call reviewing the financial results for the second quarter of 2022, at 8:00 A.M. EST on Friday, August 12th, 2022.
May 26, 2022 04:30 pm ET
CASI PHARMACEUTICALS ANNOUNCES REVERSE STOCK SPLIT
ROCKVILLE, Md. and BEIJING, May 26, 2022 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced it has filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation to implement a 1-for-10 reverse stock split that will become effective at 5:00 p.m., Eastern Time, on June 1, 2022. The primary objective of implementing a reverse split is to satisfy the minimum bid price requirement for continued listing on The NASDAQ Cap
May 24, 2022 07:00 am ET
CASI PHARMACEUTICALS ENTERES INTO SUBLICENSE AGREEMENT WITH TIANSHI PHARMACEUTICALS FOR ANTI-CD38 MONOCLONAL ANTIBODY (MAB) CID-103 IN AUTOIMMUNE FIELD
~ CASI to receive upfront payment of $10 million in two instalments ~
May 12, 2022 07:00 am ET
CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2022 FINANCIAL RESULTS
ROCKVILLE, Md. and BEIJING, May 12, 2022 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported financial results for the first quarter of 2022.
May 02, 2022 07:00 am ET
CASI PHARMACEUTICALS TO REPORT FIRST QUARTER 2022 FINANCIAL RESULTS AND HOST CONFERENCE CALL MAY 12, 2022
ROCKVILLE, Md. and BEIJING, May 2, 2022 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced the Company will host a conference call reviewing the financial results for the first quarter of 2022, at 8:00 a.m. EST on Thursday, May 12th, 2022.
Apr 01, 2022 07:00 am ET
CASI PHARMACEUTICALS STATEMENT ON STATUS UNDER HOLDING FOREIGN COMPANIES ACCOUNTABLE ACT
ROCKVILLE, Md. and BEIJING, April 1, 2022 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, announced today that on March 30, 2022, the Securities and Exchange Commission (SEC) provisionally identified CASI Pharmaceuticals Inc (CASI) on the list, pursuant to the Holding Foreign Companies Accountable Act (HFCAA), that uses an auditor not subject to Public Company Accounting Oversight Board (PCAOB) inspection.
Mar 28, 2022 07:00 am ET
CASI PHARMACEUTICALS ANNOUNCES FULL-YEAR 2021 FINANCIAL RESULTS AND FOURTH QUARTER 2021 EVOMELA® REVENUE
~ EVOMELA® (melphalan for injection) Fourth Quarter 2021 Revenue Continues Strong Upward Trend, exceeding guidance ~
Mar 23, 2022 07:00 am ET
CASI PHARMACEUTICALS TO REPORT FOURTH QUARTER AND YEAR END 2021 FINANCIAL RESULTS AND HOST CONFERENCE CALL MARCH 28, 2022
ROCKVILLE, Md. and BEIJING, March 23, 2022 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced the Company will host a conference call reviewing the financial results for the fourth quarter and for the year ended December 31st, 2021, at 8:00 a.m. EDT on Monday, March 28th, 2022.
Mar 04, 2022 06:00 am ET
CASI PHARMACEUTICALS ANNOUNCES RENEWAL OF EXCLUSIVE DISTRIBUTION AGREEMENT FOR EVOMELA® IN CHINA
ROCKVILLE, Md. and BEIJING, March 4, 2022 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, announced today, that the Company has entered into a renewal exclusive distribution agreement, whereby under the terms of the agreement, China Resources Pharmaceutical Commercial Group International Trading Co., Ltd. (CRPCGIT), previously called "China Resources Guokang Pharmaceuticals Co., Ltd. (CRGK)", will continue to be the sole distributor for the sale of EVOME
Feb 16, 2022 06:00 am ET
CASI PHARMACEUTICALS ANNOUNCES PRELIMINARY FOURTH QUARTER AND FULL-YEAR 2021 REVENUES AND PROVIDES BUSINESS UPDATES
ROCKVILLE, Md. and BEIJING, Feb. 16, 2022 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced preliminary and unaudited revenues for the fourth quarter and full-year 2021 and provided an update on key highlights for 2022.
Jan 20, 2022 06:00 am ET
CASI PHARMACEUTICALS PARTNER, BIOINVENT, ANNOUNCES BI -1206 GRANTED ORPHAN DRUG DESIGNATION BY THE U.S. FDA FOR THE TREATMENT OF PATIENTS WITH FOLLICULAR LYMPHOMA
ROCKVILLE, Md and LUND, Sweden, Jan. 20, 2022 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, announced today, that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its partner BioInvent International AB, for BI-1206, an investigational anti-FcyRllB antibody, for the treatment of follicular lymphoma (FL), the most common form of slow-growing Non-Hodgkin lymphoma (NHL).
Jan 18, 2022 06:00 am ET
CASI PHARMACEUTICALS ANNOUNCES CNCT19 (CD19 CAR-T) GRANTED ORPHAN DRUG DESIGNATION BY THE U.S. FDA
ROCKVILLE, Md. and BEIJING, Jan. 18, 2022 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, announced today, that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its partner Juventas Cell Therapy Ltd (Juventas), for CNCT19, an investigational CD-19 directed CAR-T therapy, for the treatment of patients with Acute Lymphoblastic Leukemia (ALL).
Jan 03, 2022 06:00 am ET
CASI PHARMACEUTICALS, RECEIVES NASDAQ DEFICIENCY NOTICE
ROCKVILLE, Md. and BEIJING, Jan. 3, 2022 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced that on December 30, 2021, CASI received a deficiency letter from the Listing Qualifications Department (the "Staff") of the Nasdaq Stock Market ("Nasdaq") notifying CASI that, for the previous 30 consecutive business days, the bid price of CASI's common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasda
Dec 17, 2021 06:00 am ET
CASI PHARMACEUTICALS ANNOUNCES STOCK REPURCHASE PROGRAM
ROCKVILLE, Md. and BEIJING, Dec. 17, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), (the "Company" or "CASI"), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced that its board of directors approved a stock repurchase program for the repurchase of up to USD 10 million of the Company's common stock (and no more than 12,500,000 shares of the Company's common stock) through open market purchases in compliance with Rule 10b-18 under the Securities Exchange Act of 1934 and through trading
Dec 10, 2021 07:15 am ET
BioInvent and CASI Pharmaceuticals Announce CTA Approval for Clinical Studies of BI-1206 in NHL in China
LUND, SE / ACCESSWIRE / December 10, 2021 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV) , a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA), China's medical product regulator, has approved a Clinical Trial Application (CTA) submitted by BioInvent's licensee in China, CASI Pharmaceuticals (CASI). The CTA is for the initiati
Dec 10, 2021 06:00 am ET
CASI PHARMACEUTICALS AND BIOINVENT ANNOUNCE CTA APPROVAL FOR CLINICAL STUDY OF BI-1206 IN NHL IN CHINA
ROCKVILLE, Md. and BEIJING, Dec. 10, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announces that the China National Medical Products Administration (NMPA) has approved the Company's Clinical Trial Application (CTA) for BI-1206, a First-in-class fully human monoclonal antibody ("mAb") that targets FcγRIIB. CASI is planning Phase 1 trials of BI-1206 as a single agent to evaluate the PK/safety profile and in combination with rituximab in NHL (m
Nov 15, 2021 06:00 am ET
CASI Pharmaceuticals To Present At Jefferies London Healthcare Conference
ROCKVILLE, Md., and BEIJING, Nov. 15, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announces that Mr. Larry Zhang, President of CASI Pharmaceuticals, will be presenting at the Jefferies London Healthcare Conference. Details for the virtual conference is as follows:
Nov 12, 2021 06:00 am ET
CASI Pharmaceuticals Announces Third Quarter 2021 Financial Results
ROCKVILLE, Md. and BEIJING, Nov. 12, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), is a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported financial results for the third quarter of 2021.
Nov 05, 2021 07:00 am ET
CASI Pharmaceuticals Partner, BioInvent, To Present Further Positive Clinical Data On BI-1206 At ASH 2021
ROCKVILLE, Md., and BEIJING, Nov. 5, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, announces that its partner BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, announced additional positive interim top-line data from its novel anti-FcγRIIB antibody BI-1206. The data update comes from the company's Phase
Nov 02, 2021 07:00 am ET
CASI Pharmaceuticals To Report Third Quarter 2021 Financial Results And Host Conference Call November 12, 2021
ROCKVILLE, Md. and BEIJING, Nov. 2, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced the Company will host a conference call reviewing the third quarter highlights at 8:00 a.m. EDT on Friday, November 12th, 2021.
Oct 25, 2021 07:00 am ET
CASI Pharmaceuticals Announces Partner Juventas Completion Of Series C Financing Of $63 Million (RMB410 Million) For Acceleration Of CNCT19 Pivotal Trials And Commercialization
ROCKVILLE, Md. and BEIJING, Oct. 25, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported that Juventas Cell Therapy Ltd. ("Juventas") has completed a Series C financing round through which it raised more than RMB410 million (approximately $63 million (USD)). Juventas states that the funds will be used to pursue a new drug application in China and launch implementation of a commercialization and international research and development plan f
Sep 20, 2021 07:00 am ET
CASI Pharmaceuticals, Inc. To Participate In Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
ROCKVILLE, Md. and BEIJING, Sept. 20, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, announced that Dr. Alexander Zukiwski, Chief Medical Officer of CASI Pharmaceuticals, will be presenting at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit. Details for the virtual conference is as follows.
Sep 01, 2021 09:31 am ET
Thinking about buying stock in Powerbridge Technologies, Mogo, Frontline, Tattooed Chef, or CASI Pharmaceuticals?
NEW YORK, Sept. 1, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PBTS, MOGO, FRO, TTCF, and CASI.
Aug 23, 2021 10:50 am ET
Thinking about buying stock in Sundial Growers, Palantir Technologies, Ford, CASI Pharmaceuticals, or American Airlines?
NEW YORK, Aug. 23, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SNDL, PLTR, F, CASI, and AAL.
Aug 23, 2021 08:30 am ET
Thinking about buying stock in Trillium Therapeutics, Vivos Therapeutics, Axsome Therapeutics, Orphazyme, or CASI Pharmaceuticals?
NEW YORK, Aug. 23, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TRIL, VVOS, AXSM, ORPH, and CASI.
Aug 12, 2021 07:00 am ET
CASI Pharmaceuticals Announces Second Quarter 2021 Financial Results
ROCKVILLE, Md. and BEIJING, Aug. 12, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported financial results for the second quarter of 2021.
Aug 10, 2021 07:00 am ET
CASI Pharmaceuticals To Report Second Quarter 2021 Financial Results And Host Conference Call August 12, 2021
ROCKVILLE, Md. and BEIJING, Aug. 10, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced the Company will host a conference call reviewing the second quarter highlights at 8:00 a.m. ET on Thursday, August 12th, 2021.
Jun 10, 2021 07:00 am ET
CASI Pharmaceuticals Announces Dosing Of First Patient Of CID-103 In Phase 1 Clinical Trial For Relapsed Or Refractory Multiple Myeloma
ROCKVILLE, Md. and BEIJING, June 10, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced First-Patient-In in the Phase 1 dose escalation and expansion study of CID-103, an investigational novel anti-CD38 monoclonal antibody, in patients with previously treated, relapsed or refractory multiple myeloma. The study is designed to assess the safety, tolerability, pharmacology and clinical activity of CID-103.
Feb 16, 2021 06:00 am ET
CASI Pharmaceuticals Announces Preliminary Fourth Quarter And Full-Year 2020 Revenues And Provides Business Updates
ROCKVILLE, MD., and BEIJING, Feb. 16, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced preliminary and unaudited revenues for the fourth quarter and full-year 2020 and provided an update on key highlights for 2021.
Jan 28, 2021 06:00 am ET
CASI Pharmaceuticals Partner, BioInvent, Presents Phase I/IIA Data That Suggests BI-1206 Restores Activity Of Rituximab In Relapsed Non-Hodgkin's Lymphoma Patients
ROCKVILLE, Md., and BEIJING, Jan. 28, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announces that its partner BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, announced positive interim results from the Phase I/IIa trial of the novel anti-FcγRIIB antibody BI-1206 in combination with rituximab (an
Jan 21, 2021 06:00 am ET
CASI Pharmaceuticals Partner, BioInvent, To Host Key Opinion Leader Call On BI-1206 For Relapsed Or Refractory Non-Hodgkin's Lymphoma
ROCKVILLE, Md. and BEIJING, Jan. 21, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announces that its partner BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy today announces that it will host a Key Opinion Leader call on BI-1206 for relapsed or refractory Non-Hodgkin's Lymphoma on Thursday, Januar
Jan 08, 2021 06:00 am ET
CASI Pharmaceuticals, Inc. To Present At H.C. Wainwright Bioconnect Conference
ROCKVILLE, Md., and BEIJING, Jan. 8, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announces that Dr. Wei-Wu He, Chairman and Chief Executive Officer of CASI Pharmaceuticals, will be presenting at the H.C.Wainwright Bioconnect Conference. Details for the virtual conferences are as follows.
Dec 23, 2020 08:31 am ET
Thinking about buying stock in CASI Pharmaceuticals, FuelCell Energy, Ampio Pharmaceuticals, Mohawk Group, or Perion Network?
NEW YORK, Dec. 23, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CASI, FCEL, AMPE, MWK, and PERI.
Dec 23, 2020 06:00 am ET
CASI Pharmaceuticals Announces CNCT19 (CD19 CAR-T) Receives China Breakthrough Therapy Designation
ROCKVILLE, Md., and BEIJING, Dec. 23, 2020 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announces that the Chinese Center for Drug Evaluation, a division of the China National Medical Products Association, has granted Breakthrough Therapy Designation ("Breakthrough Designation") to its partner Juventas Cell Therapy Ltd. for CNCT19, a potential CD19 CAR-T therapy for the treatment of adults with relapsed/refractory B-cell acute lymphoblastic leuke
Dec 16, 2020 06:00 am ET
CASI Pharmaceuticals Announces Appointment Of Chief Financial Officer
ROCKVILLE, Md., and BEIJING, Dec. 16, 2020 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announces the appointment of Weihao Xu to the position of Chief Financial Officer. Mr. Xu will report to Dr. Wei-Wu He, Chairman and CEO of CASI.
Nov 18, 2020 08:00 pm ET
CASI Pharmaceuticals Announces Partner Juventas Completes $65 Million Financing And Initiates Registration Study For CNCT19 (CD19 CAR-T)
ROCKVILLE, Md. and BEIJING, Nov. 18, 2020 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announces partner Juventas has completed the equivalent of $65 million financing and has initiated and enrolled the first patient in a Phase II registration study for CNCT19 (CD19 CAR-T) in China in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL).
Nov 09, 2020 06:00 am ET
CASI Pharmaceuticals Announces Third Quarter 2020 Financial Results
ROCKVILLE, Md. and BEIJING, Nov. 9, 2020 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported financial results and business highlights for the third quarter of 2020.
Nov 05, 2020 06:00 am ET
CASI Pharmaceuticals To Report Third Quarter 2020 Financial Results And Host Conference Call November 9, 2020
ROCKVILLE, MD., and BEIJING, Nov. 5, 2020 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced the Company will host a conference call reviewing third quarter highlights at 4:30 p.m. ET on Monday, November 9th, 2020.
Oct 27, 2020 07:00 am ET
BioInvent licenses anti-FcγRllB antibody BI-1206 to CASI Pharmaceuticals for Greater China region
LUND, Sweden and ROCKVILLE, Md., Oct. 27, 2020 /PRNewswire/ -- BioInvent International AB ("BioInvent" or the "Company") (OMXS: BINV), a biotechnology company focused on the discovery and development of first-in-class immune-modulatory antibodies for cancer immunotherapy, and CASI Pharmaceuticals, Inc. (NASDAQ: CASI), a U.S. biopharmaceutical company with an established clinical development and commercial infrastructure in China, today announced they have entered into an exclusive licensing agreement for the development and commercialization of novel anti-FcγRIIB antibody, BI-1206, in mainla
Aug 03, 2020 07:00 am ET
CASI Pharmaceuticals To Report Second Quarter 2020 Financial Results And Host Conference Call August 10, 2020
ROCKVILLE, Md. and BEIJING, Aug. 3, 2020 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced the Company will host a conference call reviewing the second quarter highlights at 4:30 p.m. ET on Monday, August 10th, 2020.
Jul 22, 2020 09:05 am ET
CASI Pharmaceuticals Announces Pricing Of $38,000,000 Public Offering Of Common Stock
ROCKVILLE, Md. and BEIJING, July 22, 2020 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced the pricing of an underwritten public offering of 20,000,000 shares of its common stock at a price to the public of $1.90 per share. CASI has granted the underwriters a 30-day option to purchase up to an additional 3,000,000 shares of its common stock. The offering is expected to close on or about July 24, 2020, subject to satisfaction of customary cl
Jul 21, 2020 04:01 pm ET
CASI Pharmaceuticals Announces Proposed Public Offering Of Common Stock
ROCKVILLE, Md. and BEIJING, July 21, 2020 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell shares of its common stock. In connection with the offering, CASI expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. There can be no assurances
Jun 08, 2020 07:00 am ET
CASI Pharmaceuticals Announces Submission Of Clinical Trial Application (IND) To Conduct Phase 1 Study For Anti-38 Monoclonal Antibody Program
ROCKVILLE, Md. and BEIJING, June 8, 2020 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced that it submitted a Clinical Trial Application (CTA) (IND) with the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) for CID-103, its novel anti-CD38 monoclonal antibody for the treatment of multiple myeloma and other hematological malignancies.
Jun 02, 2020 07:00 am ET
CASI Pharmaceuticals To Present At The Jefferies 2020 Healthcare Conference
ROCKVILLE, Md., and BEIJING, June 2, 2020 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced that Dr. Wei-Wu He, Chairman & CEO will present an overview of the company and provide a business update at the Jefferies 2020 Healthcare Conference on Thursday, June 4, 2020, at 4:00 p.m. ET. The conference will be held in a virtual meeting format.
May 11, 2020 07:00 am ET
CASI Pharmaceuticals Announces First Quarter 2020 Financial Results
ROCKVILLE, Md. and BEIJING, May 11, 2020 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported financial results for the first quarter of 2020.
Apr 07, 2020 07:00 am ET
CASI Pharmaceuticals To Present at 2020 Solebury Trout Virtual Investor Conference
ROCKVILLE, Md. and BEIJING, April 7, 2020 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced that Dr. Wei-Wu He, Chairman & CEO will present an overview of the company and provide a business update at the Solebury Trout Virtual Global Healthcare Series. During the 25-minute presentation, participants will be able to submit questions electronically with answers provided by the discretion of the company on an individual basis afterwards. D
Mar 16, 2020 07:00 am ET
CASI Pharmaceuticals Announces Full Year 2019 Financial Results
ROCKVILLE, Md. and BEIJING, March 16, 2020 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported financial results for the year ended December 31, 2019, and provided a business update.
Nov 12, 2019 06:00 am ET
CASI Pharmaceuticals Announces Third Quarter 2019 Financial Results
ROCKVILLE, Md. and BEIJING, Nov. 12, 2019 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing therapeutics and pharmaceutical products, today reported financial results for the third quarter and nine months ended September 30, 2019.
Nov 07, 2019 06:00 am ET
CASI Pharmaceuticals Enters Exclusive China Distribution License Agreement For Octreotide Long Acting Injectable (LAI) Microsphere For Neuroendocrine Cancers And Acromegaly
ROCKVILLE, Md. and BEIJING, Nov. 7, 2019 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, announces an exclusive distribution agreement with Pharmathen Global BV for the development and distribution of octreotide long acting injectable (LAI) microsphere in China. Octreotide LAI formulations are considered a standard of care for the treatment of acromegaly and for the control of symptoms associated with certain neuroendocrine tumors. Pharmathen has receive
Sep 19, 2019 07:00 am ET
CASI Pharmaceuticals Announces The Promotion Of Larry Zhang To President
ROCKVILLE, Md., Sept. 19, 2019 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing therapeutics and pharmaceutical products, announces the promotion of Larry Zhang to President.
Sep 16, 2019 06:00 am ET
China NMPA Accepts Clinical Trial Application For CASI's CD19 CAR-T-Product
ROCKVILLE, Md., Sept. 16, 2019 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing therapeutics and pharmaceutical products, announces that the Chinese National Medical Product Administration (NMPA), the Chinese FDA, has accepted the clinical trial application for CNCT19 (CD19 CAR-T) for investigation in relapsed B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL). CASI owns the exclusive worldwide license and commercial rights to CNCT19.
Sep 05, 2019 07:00 am ET
CASI Pharmaceuticals, Inc. to Host Key Opinion Leader Symposium on September 10, 2019 in New York City
ROCKVILLE, Md., Sept. 5, 2019 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing therapeutics and pharmaceutical products in China, U.S., and throughout the world, announces it will host a key opinion leader (KOL) symposium addressing innovations in cancer immunotherapy and recent regulatory reforms impacting the China biopharmaceutical market. The event will be held in New York City on September 10, 2019 at 11:00AM EST.
Sep 03, 2019 07:00 am ET
CASI Pharmaceuticals, Inc. To Present At The 2019 H.C. Wainwright 21st Annual Global Investment Conference
ROCKVILLE, Md., Sept. 3, 2019 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing therapeutics and pharmaceutical products in China, U.S., and throughout the world, announces it will present at the 2019 H.C. Wainwright 21st Annual Global Investment Conference being held September 8-10, 2019 in New York, NY.
Aug 12, 2019 07:00 am ET
CASI Pharmaceuticals Announces Launch of EVOMELA® (melphalan for injection) in China
ROCKVILLE, Md., Aug. 12, 2019 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing therapeutics and pharmaceutical products in China, U.S., and throughout the world, announces the product launch of EVOMELA® (melphalan for injection) in China which is the first commercial product for the Company.
Aug 09, 2019 07:00 am ET
CASI Pharmaceuticals Announces Second Quarter and First Half 2019 Financial and Business Results
ROCKVILLE, Md., Aug. 9, 2019 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing therapeutics and pharmaceutical products in China, U.S., and throughout the world, today reported financial results for the second quarter and six months ended June 30, 2019 and provided a review of recent accomplishments and anticipated milestones.
May 15, 2019 07:00 am ET
CASI Pharmaceuticals Announces First Quarter 2019 Financial and Business Results
ROCKVILLE, Md., May 15, 2019 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. pharmaceutical company with a platform to develop and accelerate the launch of innovative therapeutics and pharmaceutical products in China, the U.S., and throughout the world, today reported financial results for the first quarter 2019 and provided a review of recent accomplishments and anticipated upcoming milestones.
Apr 18, 2019 04:15 pm ET
INVESTOR ALERT: Monteverde & Associates PC Launches an Investigation of the Board of Directors and Officers
NEW YORK, April 18, 2019 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating the Board of Directors and Officers of the following companies in connection with their corresponding upcoming shareholder meeting:
Apr 17, 2019 07:00 am ET
CASI Pharmaceuticals In-Licenses Exclusive Worldwide Rights to Novel Anti-CD38 Monoclonal Antibody Program From Black Belt Therapeutics
ROCKVILLE, Md., April 17, 2019 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. pharmaceutical company with a platform to develop and accelerate the launch of innovative therapeutics and pharmaceutical products in China, the U.S., and throughout the world, announces the signing of a license agreement for exclusive worldwide rights to the investigational anti-CD38 monoclonal antibody (Mab) TSK011010 program from Black Belt Therapeutics Limited.
Apr 10, 2019 07:50 am ET
Research Report Identifies CASI Pharmaceuticals, WestRock, H. B. Fuller, Osisko Gold Royalties, Kopin, and Redfin with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of CASI Pharmaceuticals, Inc. (NASDAQ:CASI), WestRock Company (NYSE:WRK),...
Apr 02, 2019 07:00 am ET
CASI Pharmaceuticals Announces The Appointment Of Wei-Wu He, Ph.D., Executive Chairman, To The Role Of Chief Executive Officer
ROCKVILLE, Md., April 2, 2019 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. pharmaceutical company with a platform to develop and accelerate the launch of pharmaceutical products and innovative therapeutics in China, the U.S., and throughout the world, announced that Wei-Wu He, Ph.D., Executive Chairman of CASI, has been appointed Chief Executive Officer. Dr. He will continue to serve as Chairman of the Board of Directors. Dr. He succeeds Ken K. Ren, Ph.D. who for personal reasons is stepping down from his role as Chief Executive Officer but will remain on the Company's
Mar 29, 2019 07:00 am ET
CASI Pharmaceuticals Announces Fourth Quarter And Full Year 2018 Financial Results And Business Results
ROCKVILLE, Md., March 29, 2019 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. pharmaceutical company with a platform to develop and accelerate the launch of pharmaceutical products and innovative therapeutics in China, U.S., and throughout the world, today reported financial results for the fourth quarter and year ended December 31, 2018 and provided a review of recent accomplishments and anticipated upcoming milestones.
Mar 13, 2019 07:00 am ET
CASI Pharmaceuticals Announces Exclusive Distribution Partner For Melphalan Hydrochloride For Injection (EVOMELA®) In China
ROCKVILLE, Md., March 13, 2019 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. based pharmaceutical company with a platform to develop and accelerate the launch of pharmaceutical products and innovative therapeutics in China, U.S., and throughout the world, announced that the Company has entered into an exclusive distribution agreement, whereby under the terms of the agreement, China Resources Guokang Pharmaceuticals Co., Ltd. (CRGK) will be the sole distributor for the sale of melphalan hydrochloride for injection (EVOMELA®) in China.
Mar 07, 2019 06:00 am ET
CASI Pharmaceuticals Announces China National Medical Products Administration (NMPA) Approval Of CTA To Conduct Registration Trial For MARQIBO®
ROCKVILLE, Md., March 7, 2019 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. based pharmaceutical company with a platform to develop and accelerate the launch of pharmaceutical products and innovative therapeutics in China, U.S., and throughout the world, announced that the National Medical Products Administration (NMPA) has approved the Company's Clinical Trial Application (CTA) allowing for a registration clinical trial to evaluate the efficacy and safety of vincristine sulfate LIPOSOME injection (MARQIBO®).
Feb 20, 2019 08:15 am ET
Report: Developing Opportunities within Pure Storage, Flowers Foods, Cognex, CASI Pharmaceuticals, Ellie Mae, and Douglas Emmett — Future Expectations, Projections Moving into 2019
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Pure Storage, Inc. (NYSE:PSTG), Flowers Foods, Inc. (NYSE:FLO), Cognex...
Feb 19, 2019 06:00 am ET
CASI Pharmaceuticals Announces China National Medical Products Administration (NMPA) Approval Of CTA To Conduct Confirmatory Clinical Trial For ZEVALIN®
ROCKVILLE, Md., Feb. 19, 2019 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. based pharmaceutical company with a platform to develop and accelerate the launch of pharmaceutical products and innovative therapeutics in China, U.S., and throughout the world, today announced that the National Medical Products Administration (NMPA) has approved the Company's Clinical Trial Application (CTA) to allow for a confirmatory clinical trial to evaluate the efficacy and safety of ibritumomab tiuxetan injection (ZEVALIN®). Ibritumomab tiuxetan (ZEVALIN®) is a U.S. Food and Drug Administ
Feb 06, 2019 06:00 am ET
CASI Pharmaceuticals to Present at the BIO CEO & Investor Conference
ROCKVILLE, Md., Feb. 6, 2019 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to the development and delivery of high quality, cost-effective pharmaceutical products and innovative therapeutics to patients in China and throughout the world, announces it will present at the BIO CEO & Investor Conference being held February 11-12, 2019 in New York City, New York.
Dec 03, 2018 07:12 am ET
CASI Pharmaceuticals Announces China Market Approval Of Melphalan Hydrochloride For Injection (Trademark: EVOMELA®)
ROCKVILLE, Md., Dec. 3, 2018 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to the development and delivery of high quality, cost-effective pharmaceutical products and innovative therapeutics to patients in China and throughout the world, announces today that it has received National Medical Products Administration ("NMPA") (formerly, the China FDA) approval of Melphalan Hydrochloride For Injection (EVOMELA®), for:
Nov 28, 2018 08:40 am ET
Report: Exploring Fundamental Drivers Behind CASI Pharmaceuticals, Booking, Enstar Group, Madrigal Pharmaceuticals, Dermira, and Kaiser Aluminum — New Horizons, Emerging Trends, and Upcoming Developme
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of CASI Pharmaceuticals, Inc. (NASDAQ:CASI), Booking Holdings Inc....
Nov 16, 2018 06:00 am ET
CASI Pharmaceuticals To Build GMP Manufacturing Site In Wuxi, China
ROCKVILLE, Md., Nov. 16, 2018 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to the development and delivery of high quality, cost-effective pharmaceutical products and innovative therapeutics to patients in China and throughout the world, announces that it has entered into framework agreements to build a state-of-the-art manufacturing site strategically located in the Wuxi Huishan Economic Development Zone in Jiangsu Province, China. The Wuxi Huishan Economic Development Zone is a leading science and technology innovation center in the regi
Nov 14, 2018 06:00 am ET
CASI Pharmaceuticals Announces Third Quarter and First Nine Months 2018 Financial and Business Results
ROCKVILLE, Md., Nov. 14, 2018 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to the development and delivery of high quality, cost-effective pharmaceutical products and innovative therapeutics to patients in the U.S., China and throughout the world, today reported financial results for the third quarter and nine months ended September 30, 2018 and provided a review of recent accomplishments and anticipated upcoming milestones.
Oct 23, 2018 07:05 am ET
CASI Pharmaceuticals Acquires HBV ANDA from Laurus Labs Limited
ROCKVILLE, Md., Oct. 23, 2018 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to the development and delivery of high quality, cost-effective pharmaceutical products and innovative therapeutics to patients in China and throughout the world, announces that it has acquired a U.S. FDA-approved abbreviated new drug application (ANDA) from Laurus Labs Limited. The drug, tenofovir disoproxil fumarate (TDF), is indicated for the treatment of hepatitis B virus (HBV). As part of the transaction, CASI will make certain upfront and milestone payments in
Oct 18, 2018 08:40 am ET
Detailed Research: Economic Perspectives on Beacon Roofing Supply, Rowan Companies, CASI Pharmaceuticals, LivePerson, Impinj, and Tredegar — What Drives Growth in Today's Competitive Landscape
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Beacon Roofing Supply, Inc. (NASDAQ:BECN), Rowan Companies PLC...
Oct 02, 2018 07:00 am ET
CASI Pharmaceuticals Announces Appointment Of President To Its China Operations To Lead Commercialization
ROCKVILLE, Md., Oct. 2, 2018 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to the development and delivery of high quality, cost-effective pharmaceutical products and innovative therapeutics to patients in the U.S., China and throughout the world, announces the appointment of Larry Zhang to the position of President of CASI (Beijing) Pharmaceuticals Co., Ltd., the China operating subsidiary of CASI Pharmaceuticals, Inc. headquartered in Rockville, Maryland.
Sep 28, 2018 07:00 am ET
CASI Pharmaceuticals Announces Appointment Of Chief Financial Officer
ROCKVILLE, Md., Sept. 28, 2018 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to the development and delivery of high quality, cost-effective pharmaceutical products and innovative therapeutics to patients in the U.S., China and throughout the world, announces the appointment of George Chi to the position of Chief Financial Officer.
Sep 14, 2018 07:00 am ET
CASI Pharmaceuticals Announces $48.5 Million Private Placement
ROCKVILLE, Md., Sept. 14, 2018 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to the development and delivery of high quality, cost-effective pharmaceutical products and innovative therapeutics to patients in the U.S., China and throughout the world, announces today a $48.5 million private placement. The Company has entered into definitive securities purchase agreements pursuant to which the Company will issue 9,048,504 shares of its Common Stock with accompanying warrants to purchase 2,714,548 shares of its Common Stock. The purchase price f
Aug 27, 2018 08:20 am ET
Factors of Influence in 2018, Key Indicators and Opportunity within Steelcase, SecureWorks, Cleveland-Cliffs, Tredegar, Warrior Met Coal, and CASI Pharmaceuticals — New Research Emphasizes Economic Gr
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Steelcase Inc. (NYSE:SCS), SecureWorks Corp. (NASDAQ:SCWX),...
Aug 14, 2018 07:00 am ET
CASI Pharmaceuticals Announces Second Quarter And First Half 2018 Financial And Business Results
ROCKVILLE, Md., Aug. 14, 2018 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to the development and delivery of high quality, cost-effective pharmaceutical products and innovative therapeutics to patients in the U.S., China and throughout the world, today reported financial results for the second quarter and six months ended June 30, 2018 and provided a review of recent accomplishments and anticipated upcoming milestones.
Jul 03, 2018 01:05 pm ET
CASI Pharmaceuticals Added To Russell 2000®, 3000® And Microcap® Indexes
ROCKVILLE, Md., July 3, 2018 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to the development and delivery of high quality, cost-effective pharmaceutical products and innovative therapeutics to patients in the U.S., China and throughout the world, announces that the company has been added to the Russell 2000®, 3000® and Microcap® Indexes, effective after U.S. market closed on Friday, June 22, 2018.
Jun 25, 2018 08:00 am ET
Report: Exploring Fundamental Drivers Behind Cabot Oil & Gas, Chesapeake Lodging Trust, CASI Pharmaceuticals, Peabody Energy, Alcoa, and Edwards Lifesciences — New Horizons, Emerging Trends, and Upcom
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Cabot Oil Gas Corporation (NYSE:COG), Chesapeake Lodging Trust...
Jun 21, 2018 07:00 am ET
CASI Pharmaceuticals Enters Strategic Partnering And Contract Manufacturing Agreement With Yiling Wanzhou International Pharmaceuticals For Entecavir And Cilostazol
ROCKVILLE, Md., June 21, 2018 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to the development and delivery of high quality, cost-effective pharmaceutical products and innovative therapeutics to patients in the U.S., China and throughout the world, announces a strategic and long-term manufacturing agreement with Yiling Wanzhou International Pharmaceutical Co., Ltd. for the manufacturing of entecavir and cilostazol. Yiling Wanzhou International Pharmaceutical Co., Ltd. is a subsidiary of Shijiazhuang Yiling Pharmaceutical Co. Ltd. The contrac
May 29, 2018 07:00 am ET
CASI Pharmaceuticals To Present At The BIO International Convention
ROCKVILLE, Md., May 29, 2018 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to the development and delivery of high quality, cost-effective pharmaceutical products and innovative therapeutics to patients in the U.S., China and throughout the world, announces it will present at the BIO International Convention, June 4-7, 2018 in Boston, MA.
May 15, 2018 07:00 am ET
CASI Pharmaceuticals Announces First Quarter 2018 Financial And Business Results
ROCKVILLE, Md., May 15, 2018 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to the development and delivery of high quality, cost-effective pharmaceutical products and innovative therapeutics to patients in the U.S., China and throughout the world, today reported financial results for the first quarter and provided a review of recent accomplishments and anticipated upcoming milestones.
May 07, 2018 07:30 am ET
Detailed Research: Economic Perspectives on CASI Pharmaceuticals, Energy Transfer Partners, Cypress Semiconductor, Xcel Energy, Ironwood Pharmaceuticals, and KalVista Pharmaceuticals — What Drives Gro
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of CASI Pharmaceuticals, Inc. (NASDAQ:CASI), Energy Transfer Partners, L.P....
Apr 05, 2018 08:00 am ET
CASI Pharmaceuticals Provides Update On EVOMELA®
ROCKVILLE, Md., April 5, 2018 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to bringing high quality, cost-effective pharmaceutical products and innovative oncology therapeutics to patients, announces receipt of a letter from the Center for Drug Evaluation (CDE) (group within the China FDA in charge of technical review) indicating that EVOMELA® (melphalan) for injection has been scheduled for review by the Expert Advisory Anti-Tumor (Oncology) Drugs Committee (the "Advisory Committee"), which is scheduled to take place between April 25-26,
Apr 03, 2018 07:00 am ET
CASI Pharmaceuticals To Present At The H.C. Wainwright Global Life Sciences Conference
ROCKVILLE, Md., April 3, 2018 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to bringing high quality, cost-effective pharmaceutical products and innovative oncology therapeutics to patients, announces it will present at the H.C. Wainwright Global Life Sciences Conference, April 8 – 10, 2018 in Monte Carlo, Monaco.
Mar 29, 2018 07:00 am ET
CASI Pharmaceuticals Announces Fourth Quarter And Full Year 2017 Financial Results
ROCKVILLE, Md., March 29, 2018 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to bringing high quality, cost-effective pharmaceutical products and innovative oncology therapeutics to patients, today reported financial results for the fourth quarter and year ended December 31, 2017 and provided a review of recent accomplishments and anticipated upcoming milestones.
Mar 20, 2018 09:29 am ET
CASI Pharmaceuticals Announces $50 Million Private Placement To Prepare Company For Commercialization In China
ROCKVILLE, Md., March 20, 2018 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to bringing high quality, cost-effective pharmaceutical products and innovative oncology therapeutics to patients, announces today a $50 million private placement. The Company has entered into definitive securities purchase agreements pursuant to which the Company will issue 15,432,091 shares of its Common Stock with accompanying warrants to purchase 6,172,832 shares of its Common Stock. The purchase price for each share of Common Stock and warrant is $3.24. The wa
Mar 05, 2018 08:30 am ET
Factors of Influence in 2018, Key Indicators and Opportunity within Cypress Semiconductor, Abaxis,Inc, Universal Health Services, CASI Pharmaceuticals, Energy Transfer Partners, and Arconic — New Rese
NEW YORK, March 05, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Cypress Semiconductor Corporation (NASDAQ:CY), Abaxis,Inc. (NASDAQ:ABAX),...
Feb 09, 2018 06:00 am ET
CASI Pharmaceuticals to Present at the BIO CEO & Investor Conference
ROCKVILLE, Md., Feb. 9, 2018 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to bringing high quality, cost-effective pharmaceutical products and innovative oncology therapeutics to patients, announces it will present at the BIO CEO & Investor Conference being held February 12-13, 2018 in New York City, New York.
Jan 26, 2018 04:00 pm ET
CASI Pharmaceuticals Acquires ANDA Portfolio From Sandoz Inc. (Sandoz)
ROCKVILLE, Md., Jan. 26, 2018 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to bringing quality pharmaceutical products to the Chinese and U.S. markets announced today that it has acquired a portfolio of 25 U.S. FDA-approved abbreviated new drug applications (ANDAs), one ANDA that FDA tentatively approved, and three ANDAs that are pending FDA approval. CASI intends to select and commercialize certain products from the portfolio that have unique market opportunity and cost-effective manufacturing in China and/or in the U.S.
Dec 01, 2017 06:00 am ET
CASI Pharmaceuticals Announces Poster Presentation At The 2017 San Antonio Breast Cancer SymposiumTM (SABCS) On ENMD-2076 In Patients With Triple-Negative Breast Cancer (TNBC)
ROCKVILLE, Md., Dec. 1, 2017 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs announces a poster presentation on ENMD-2076 at the 2017 San Antonio Breast Cancer SymposiumTM (SABCS), December 5-9, 2017 in San Antonio, Texas.
Nov 14, 2017 07:00 am ET
CASI Pharmaceuticals Reports Third Quarter 2017 Financial Results
ROCKVILLE, Md., Nov. 14, 2017 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (the "Company") (Nasdaq: CASI), a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China, today reported financial results for the three and nine months ended September 30, 2017.
Nov 02, 2017 08:15 am ET
Analysis: Positioning to Benefit within Tandem Diabetes Care, CASI Pharmaceuticals, SAExploration, Roka Bioscience, VirnetX, and PhaseRx – Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, Nov. 02, 2017 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Tandem Diabetes Care, Inc. (NASDAQ:TNDM), CASI...
Oct 13, 2017 11:00 am ET
CASI Pharmaceuticals Announces $23.8 Million Registered Direct Offering Led By Existing Shareholders
ROCKVILLE, Md., Oct. 13, 2017 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (the "Company") (Nasdaq: CASI), a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China, announced that it has entered into definitive agreements with certain institutional and accredited investors, including existing shareholders, to purchase approximately $23.8 million of securities in a registered direct offering. CASI expects to receive net proceeds of
Sep 07, 2017 08:00 am ET
CASI Provides Pipeline Development Update
ROCKVILLE, Md., Sept. 7, 2017 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs today provided an update to its pipeline.
Sep 06, 2017 08:00 am ET
CASI Pharmaceuticals To Present At The Annual Rodman & Renshaw Global Investment Conference
ROCKVILLE, Md., Sept. 6, 2017 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs announces it will present at the 19th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held on September 10-12, 2017 at Lotte New York Palace Hotel in New York City.
Aug 14, 2017 08:00 am ET
CASI Pharmaceuticals Reports Second Quarter 2017 Financial Results
ROCKVILLE, Md., Aug. 14, 2017 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs, today reported financial results for the three and six months ended June 30, 2017.
May 30, 2017 08:00 am ET
CASI Pharmaceuticals Announces Poster Presentation At ASCO On ENMD-2076 In Patients With Clear Cell Ovarian Carcinoma (CCOC)
ROCKVILLE, Md., May 30, 2017 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs announces a poster presentation on ENMD-2076 at the American Society of Clinical Oncology Annual Meeting being held June 2 – 6, 2017 in Chicago. ENMD-2076 is currently in a Phase 2 trial for the treatment of clear cell ovarian carcinoma (CCOC) at Princess Margaret Hospital Centre in Toronto. The poster will be presented in the sessions listed below and will be available on the CASI Pharmaceu
May 18, 2017 08:00 am ET
CASI Pharmaceuticals Announces Abstract On ENMD-2076 In Clear Cell Ovarian Cancer
ROCKVILLE, Md., May 18, 2017 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs today reported the availability of an abstract titled "Phase II Clinical and Molecular Trial of Oral ENMD-2076 in Clear Cell Ovarian Cancer (CCOC)" that was published on May 17, 2017 and is the subject of a poster to be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting to be held June 2-6, 2017 in Chicago, Illinois. The abstract is available at: http://abstracts.asco.
May 15, 2017 08:00 am ET
CASI Pharmaceuticals Reports First Quarter 2017 Financial Results
ROCKVILLE, Md., May 15, 2017 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs today reported financial results for the three months ended March 31, 2017.
Apr 14, 2017 08:00 am ET
CASI Pharmaceuticals Reports On Enrollment Status Of ENMD-2076 Phase 2 Study In Triple-Negative Breast Cancer
ROCKVILLE, Md., April 14, 2017 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs, reported today that along with the investigators a decision has been reached to stop further patient enrollment in its Phase 2, open-label study of ENMD-2076 in previously treated locally advanced or metastatic triple-negative breast cancer (TNBC) conducted at the University of Colorado, Denver and the Indiana University Melvin and Bren Simon Cancer Center. The study was a 2 stage design w
Mar 31, 2017 08:00 am ET
CASI Pharmaceuticals Reports 2016 Fourth Quarter And Full Year Financial Results
ROCKVILLE, Md., March 31, 2017 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs, today reported financial results for the three and 12 months ended December 31, 2016.
Mar 28, 2017 08:00 am ET
CASI Pharmaceuticals Announces Poster Presentations At AACR Annual Meeting
ROCKVILLE, Md., March 28, 2017 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs, announced today two poster presentations at the American Association for Cancer Research annual meeting. The first poster to be presented on April 3 is entitled "Evaluation of ENMD-2076 in Combination with Anti-PD1 in Syngeneic Cancer Models" and the second poster to be presented on April 4 is entitled "Kinase Inhibitor Demonstrates Efficacy in Patient Derived Xenograft Model of Fibrolamell
Dec 05, 2016 07:00 am ET
CASI Pharmaceuticals' Import Drug Registration Application For EVOMELA® Accepted For Review By CFDA
ROCKVILLE, Md., Dec. 5, 2016 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs, announced today that China's Food and Drug Administration (CFDA) has accepted for review the Company's import drug registration application for EVOMELA® (melphalan) for Injection.
Nov 14, 2016 07:00 am ET
CASI Pharmaceuticals Reports Third Quarter 2016 Financial Results
ROCKVILLE, Md., Nov. 14, 2016 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs, today reported financial results for the three and nine months ended September 30, 2016.
Aug 16, 2016 08:00 am ET
CASI Pharmaceuticals Provides Update On Phase 2 Trial Of ENMD-2076 In Fibrolamellar Carcinoma
ROCKVILLE, Md., Aug. 16, 2016 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs, today announced that its Phase 2 trial of ENMD-2076 in fibrolamellar carcinoma (FLC) has met its Stage 1 endpoint of objective response for non-futility based on the pre-specified interim analysis criteria and will advance to Stage 2 development.
Aug 15, 2016 08:00 am ET
CASI Pharmaceuticals Reports Second Quarter 2016 Financial Results
ROCKVILLE, Md., Aug. 15, 2016 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs, today reported financial results for the three and six months ended June 30, 2016.
Jun 01, 2016 08:00 am ET
CASI Pharmaceuticals Announces Poster Presentation At ASCO On ENMD-2076 In Patients With Ovarian Clear Cell Carcinoma (OCCC)
ROCKVILLE, Md., June 1, 2016 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs, announces a poster presentation on ENMD-2076 at the American Society of Clinical Oncology Annual Meeting. ENMD-2076 is currently in a Phase 2 trial for the treatment of ovarian clear cell carcinoma (OCCC) at Princess Margaret Hospital Centre in Toronto. ASCO will be held June 3 – 7, 2016 in Chicago. The poster will be presented in the session listed below and will be available on the CASI P
May 13, 2016 08:00 am ET
CASI Pharmaceuticals Reports First Quarter 2016 Financial Results
ROCKVILLE, Md., May 13, 2016 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs today reported financial results for the three months ended March 31, 2016.
May 12, 2016 08:00 am ET
CASI Pharmaceuticals Receives Approval From CFDA To Conduct Phase 2 Clinical Trial With ENMD-2076 For Fibrolamellar Carcinoma (FLC)
ROCKVILLE, Md., May 12, 2016 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs, announces that China's Food and Drug Administration (CFDA) has approved the Company's application to conduct a Phase 2 clinical trial in fibrolamellar carcinoma (FLC) patients in China for its proprietary drug candidate, ENMD-2076.
Apr 18, 2016 08:00 am ET
James E. Goldschmidt, Ph.D. Joins CASI Pharmaceuticals As Vice President Of Business Development
ROCKVILLE, Md., April 18, 2016 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs, welcomes James E. Goldschmidt, Ph.D. to lead its business development team. Dr. Goldschmidt is responsible for developing new partnerships and brings to the Company more than 25 years of biotechnology and pharmaceutical experience, including most recently at Macrophage Therapeutics, and prior thereto at ImmuneXcite, TetraLogic Pharmaceuticals, Johnson & Johnson, Wyeth Pharmaceuticals, a
Mar 28, 2016 08:00 am ET
CASI Pharmaceuticals Reports 2015 Fourth Quarter And Full Year Financial Results
ROCKVILLE, Md., March 28, 2016 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs, today reported financial results for the three and 12 months ended December 31, 2015.
Jan 19, 2016 08:30 am ET
CASI Pharmaceuticals Announces Initial Closing Of Its Strategic Financing With Receipt Of $10.3 Million Proceeds
ROCKVILLE, Md., Jan. 19, 2016 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs, announces it has received approximately $10.3 million in a strategic financing previously announced on September 21, 2015. The initial closing yielded approximately $10.1 million after minimum offering expenses. The Company closed on 8,448,613 shares of Common Stock, priced at $1.190 per share, and 1,689,722 warrants, with a purchase price of $0.125 per warrant. The warrants will become ex
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.